Manas AI
- Company typePrivate
- Founded2025
- HeadquartersSan Francisco, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
Manas AI firmographics
Firmographics- Name
- Manas AI
- Legal name
- Manas AI
- Website
- https://manasai.co
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Manas AI industry classification
Industry- Product category
- AI Drug Discovery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
- akta.pro secondary industries
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)
Keywords
Where Manas AI is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Manas AI business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Revenue model
- Pre-revenue biopharma pipeline: Manas AI is an early-stage AI-native biopharmaceutical company building its own therapeutic pipeline; the company has not disclosed product revenue and is currently funded by venture capital. Future revenue is expected to come from out-licensing, milestone payments, partnerships, and/or commercialization of internally developed drug candidates.
- Strategic platform and co-development agreements: Multi-year platform access agreements (e.g., with Schrödinger) and joint AI drug discovery collaborations with biotech (e.g., Immuneel Therapeutics) generate milestone-based collaboration and licensing revenue over time.
Go-to-market motion3 records
Distribution channels2 records
Marketing channels7 records
Manas AI product offering
Product offeringCore offering
Manas AI builds and operates a full-stack, AI-native drug discovery and development platform powered by proprietary neuro-symbolic, science-based foundational models that codify domain rules from chemistry, physics, and biology. The platform spans target identification through clinical trials, covers small molecules, antibodies/nanobodies, and siRNA modalities, and is complemented by an internal therapeutic pipeline initially targeting triple-negative breast cancer, prostate cancer, and lymphoma. Commercial access is delivered through bespoke multi-year strategic platform agreements and co-development collaborations with pharma, biotech, and technology partners.
Product overview
Manas AI offers a single unified, full-stack AI-native biopharmaceutical platform rather than a platform-plus-modules architecture: a proprietary neuro-symbolic, science-based AI foundation that drives the entire drug discovery pipeline from target identification through clinical trials across small molecules, antibodies/nanobodies, and siRNA modalities. Within this unified platform, several named offerings are highlighted as flagship components: Project Cosmos (the initiative to map the fundamental 'rules' of drug binding), the AI 'World Model' for Novel Binders (a first-in-class physics-based atomic oracle for identifying binders to disease-relevant target proteins), and Proprietary AI Filters and Bespoke Chemical Libraries (high-speed candidate selection and generative chemistry tooling). These components are tightly coupled and depend on a deep multi-year technical integration with Schrödinger's physics-based computational molecular discovery platform, supported by large-scale compute on Microsoft Azure.
Differentiator
Problem solved
Functional benefit
Products and services
- Manas AI Platform Full-stack, AI-native drug discovery and development platform built on proprietary neuro-symbolic, science-based foundational models that codify deep domain rules from chemistry, physics, and biology. The platform spans target identification through clinical trials, supports multiple therapeutic modalities (small molecules, antibodies, siRNA therapies), and combines AI with human-in-the-loop expertise to accelerate therapeutic candidate selection for pharma, biotech, and clinical-stage cell/gene therapy partners.
- Internal Oncology Therapeutic Pipeline
Quantifiable outcome
- 100x faster molecular docking speeds vs. traditional systems (via Microsoft Azure compute)
- +2 more outcomes
Companies that use Manas AI
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Manas AI technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability5 records
Feature8 records
Manas AI partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and flagship.
- Immuneel TherapeuticscoreStrategic collaboration to explore AI-driven frameworks for developing next-generation biologics, antibody-drug conjugates, and gene-based therapies for cancer and autoimmune disorders. Combines Manas AI's neuro-symbolic discovery models with Immuneel's R&D, translational science, and GMP-grade biomanufacturing capabilities to establish an end-to-end feedback loop from in silico design through scalable manufacturing.
- Schrödinger, Inc.flagshipMulti-year strategic agreement granting Manas AI deep, bespoke access to Schrödinger's industry-leading physics-based computational molecular discovery platform, combined with expert support. Designed to harmonize Manas AI's algorithms with Schrödinger's predictive power at ultra-large scale across modalities (small molecules, nanobodies, siRNA). Financial terms undisclosed.
- MicrosoftflagshipManas AI uses Microsoft Azure as its cloud computing platform and draws upon Microsoft's deep domain knowledge in AI to develop novel medicines. Through this collaboration, Manas AI builds on Azure infrastructure to enable molecular docking at speeds 100x faster than traditional systems. Peter Lee from Microsoft publicly endorsed the partnership at launch.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Manas AI competitors and assessment
Company assessmentDirect peers
- Insilico Medicine: AI-native biopharmaceutical company operating end-to-end drug discovery across multiple modalities (small molecules and beyond) with its own proprietary pipeline, comparable to Manas AI's multi-modality, pipeline-owning model.
- Recursion Pharmaceuticals: AI-driven biopharma combining high-throughput biology with machine learning to develop its own pipeline of therapeutics — directly comparable to Manas AI's AI-native, pipeline-owning, multi-modality approach.
- Isomorphic Labs: Alphabet-backed AI drug discovery company applying deep learning to molecular design across multiple therapeutic areas; pursues both partnership and proprietary pipeline models, closely paralleling Manas AI's strategy.
- Xaira Therapeutics: AI-native drug discovery startup founded in 2024 with substantial founding capital and an end-to-end discovery-and-development model across modalities — the closest comparable on stage and strategic posture to Manas AI.
- Generate:Biomedicines: AI-first biopharma developing generative biology across multiple modalities including antibodies and small molecules, with its own pipeline — directly comparable to Manas AI's multi-modality generative discovery model.
- AbCellera Biologics: AI-enabled antibody discovery platform with its own pipeline of therapeutic antibodies, directly overlapping Manas AI's antibody/nanobody discovery capability and partnership-driven biotech model.
- Atomwise: AI-driven small molecule drug discovery company combining proprietary ML with virtual screening to identify novel binders — overlapping Manas AI's small-molecule AI discovery and partnership approach.
Broad incumbents
- Schrödinger, Inc. Established physics-based computational drug discovery platform with both software and proprietary therapeutics businesses; also a Manas AI strategic partner and the broader incumbent whose platform technology Manas AI's neuro-symbolic stack builds upon.
Emerging players
- Cradle Biosciences: Early-stage AI protein engineering company focused on generative biology for therapeutic discovery — a more focused emerging competitor that overlaps with Manas AI's protein/binder design objectives.
- EvolutionaryScale: Recently launched AI biology foundation-model company pursuing frontier biological model development; an emerging player with thematic overlap to Manas AI's neuro-symbolic, science-based foundation-model approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Manas AI social profiles
Digital presenceManas AI financial estimates
Financial estimateRevenue estimate
Valuation estimate
Manas AI leadership team
Management profileNumber of profiles
Profiles14 records
Manas AI funding detail
Funding detailFunding overview
Funding rounds2 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Manas AI M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Manas AI
What does Manas AI do?
Manas AI builds and operates a full-stack, AI-native drug discovery and development platform powered by proprietary neuro-symbolic, science-based foundational models that codify domain rules from chemistry, physics, and biology. The platform spans target identification through clinical trials, covers small molecules, antibodies/nanobodies, and siRNA modalities, and is complemented by an internal therapeutic pipeline initially targeting triple-negative breast cancer, prostate cancer, and lymphoma. Commercial access is delivered through bespoke multi-year strategic platform agreements and co-development collaborations with pharma, biotech, and technology partners.
Is Manas AI a public or private company?
Manas AI is a private company. It is classified as venture growth investor backed and is currently operating.
When was Manas AI founded?
Manas AI was founded in 2025. It employs 1 to 10 people.
Where is Manas AI based?
Manas AI is headquartered in San Francisco, United States, in the North America region.
How does Manas AI make money?
Two revenue lines are on record. Pre-revenue biopharma pipeline is the primary driver. The others are strategic platform and co-development agreements.
Who are Manas AI's main competitors?
Direct peers on record are Insilico Medicine, Recursion Pharmaceuticals, Isomorphic Labs, Xaira Therapeutics, Generate:Biomedicines, AbCellera Biologics and Atomwise. Schrödinger, Inc. is listed as a broad incumbent. Emerging players are Cradle Biosciences and EvolutionaryScale.
Does Manas AI have an API?
No public API is recorded for Manas AI.
What industry is Manas AI in?
Manas AI's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 2834.